News | April 26, 2024
Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
The proposed facility is expected to be operational around January, 2027
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Around 7% of the Indian population suffers from IBS
Subscribe To Our Newsletter & Stay Updated
